公开(公告)号：US10265421B2

公开(公告)日：2019-04-23

申请号：US14764568

申请日：2014-01-30

Applicant: BRACCO IMAGING S.P.A.

Inventor： Pernille Rose Jensen ,  Lerche H. Mathilde ,  Magnus Karlsson ,  Claudia Cabella ,  Sonia Colombo Serra ,  Luigi Miragoli ,  Luca Venturi ,  Fabio Tedoldi

IPC: A61B5/055 ,  A61K49/10 ,  A61K51/04

Abstract: The invention relates to a method of Magnetic Resonance (MR) detection, in particular 13C-MR detection, by using a diagnostic medium comprising a hyperpolarized ester, in particular ethyl acetoacetate. The method comprises the detection of the MR signal of a hyperpolarized 13C carboxylic ester and of its respective hyperpolarized metabolite.

公开(公告)号：US10265398B2

公开(公告)日：2019-04-23

申请号：US15343580

申请日：2016-11-04

Applicant: WISCONSIN ALUMNI RESEARCH FOUNDATION

Inventor： Jamey Weichert ,  Anatoly Pinchuk ,  Wolfgang Axel Tomé

IPC: A61K49/00 ,  A61K51/04 ,  G01N33/58 ,  C07F9/10 ,  A61K41/00 ,  A61K49/08 ,  A61K49/10 ,  G01N33/574 ,  A61N5/10 ,  G01N33/60 ,  C07F9/6515 ,  C07F9/6524 ,  C07F9/6561 ,  C07F9/09 ,  C07F9/11 ,  A61K39/00

Abstract: Alkylphosphocholine analogs incorporating a chelating moiety that is chelated to gadolinium are disclosed herein. The alkylphophocholine analogs are compounds having the formula: or a salt thereof. R1 includes a chelating agent that is chelated to a gadolinium atom; a is 0 or 1; n is an integer from 12 to 30; m is 0 or 1; Y is —H, —OH, —COOH, —COOX, —OCOX, or —OX, wherein X is an alkyl or an arylalkyl; R2 is —N+H3, —N+H2Z, —N+HZ2, or —N+Z3, wherein each Z is independently an alkyl or an aroalkyl; and b is 1 or 2. The compounds can be used to detect solid tumors or to treat solid tumors. In detection/imaging applications, the gadolinium emits signals that are detectable using magnetic resonance imaging. In therapeutic treatment, the gadolinium emits tumor-targeting charged particles when exposed to epithermal neutrons.

公开(公告)号：US10253052B2

公开(公告)日：2019-04-09

申请号：US15203602

申请日：2016-07-06

Applicant: Five Eleven Pharma Inc.

Inventor： Hank F. Kung ,  Zehui Wu ,  Seok Rye Choi ,  Karl Plössl ,  Zhihao Zha

IPC: A61K51/04 ,  A61K49/10 ,  C07F9/38 ,  C07F9/6515 ,  C07F9/6524

Abstract: The present invention relates to compounds according to Formula I or Formula II, which are potential bone imaging agents. Certain compounds labeled with 68Ga displayed excellent bone uptake and retention. The present invention also relates to pharmaceutical compositions comprising a pharmaceutical acceptable carrier and a compound of Formula I or Formula II or a pharmaceutically acceptable salt thereof.

公开(公告)号：US10245328B2

公开(公告)日：2019-04-02

申请号：US15110386

申请日：2015-01-08

Applicant: KYUNGPOOK NATIONAL UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATION

Inventor： Tae-Jeong Kim ,  Yong Min Chang

IPC: C07D257/02 ,  A61K49/06 ,  A61K49/08 ,  A61K49/10 ,  C07F5/00

Abstract: The present disclosure relates to a magnetic resonance imaging (MRI) contrast agent containing a gadolinium complex, and more specically, to a DO3A-tranexamic acid compound having a structure of a chemical formula 1, or an ester compound thereof, and gadolinium complexes thereof. The DO3A-tranexamic acid compound or the ester compound thereof may be used to prepare gadolinium complexes. The gadolinium complexes exhibit thermodynamic and kinetic stabilities, and show the relaxation rate equal to that of the clinical contrast agent which is currently commercially available. Therefore, the gadolinium complexes can be widely used as an MRI contrast agent.

公开(公告)号：US20190060490A1

公开(公告)日：2019-02-28

申请号：US15771786

申请日：2016-10-27

Applicant: THE JOHNS HOPKINS UNIVERSITY

Inventor： WOJCIECH LESNIAK ,  SRIDHAR NIMMAGADDA ,  NIKITA OSKOLKOV ,  MICHAEL MCMAHON ,  XIAOLEI SONG ,  MARTIN G. POMPER

IPC: A61K49/12 ,  A61K49/16 ,  A61K51/06 ,  A61K51/04 ,  A61K49/10 ,  C08G73/02 ,  C08G83/00

Abstract: PAMAM dendrimer based CEST imaging agents, pharmaceutical compositions comprising the same and methods of uses thereof are disclosed.

公开(公告)号：US10202342B2

公开(公告)日：2019-02-12

申请号：US12975655

申请日：2010-12-22

Applicant: Joseph P. Y. Kao ,  Scott R. Burks ,  Gerald R. Rosen

Inventor： Joseph P. Y. Kao ,  Scott R. Burks ,  Gerald R. Rosen

IPC: C07D207/46 ,  A61K49/00 ,  A61K49/10 ,  A61K49/18 ,  A61K49/20 ,  C07D211/94 ,  C07D403/06 ,  A61B5/055 ,  G01N33/542 ,  G01N33/543 ,  G01N33/574 ,  G01R33/60 ,  A61B5/00

Abstract: The present invention relates to nitroxide imaging probes that are isotopically modified or unmodified. Such nitroxide imaging probes may be included in liposomes that encapsulate self-quenching concentrations thereof, wherein the liposomes optionally comprise a targeting ligand specific to and having affinity for targeted tissue.

公开(公告)号：US20180256758A1

公开(公告)日：2018-09-13

申请号：US15937681

申请日：2018-03-27

Applicant: Case Wester Reserve University

Inventor： Nicole F. Steinmetz ,  Michael Bruckman ,  Lauren Randolph

IPC: A61K49/18 ,  A61K49/10 ,  A61K49/08

CPC classification number: A61K49/1896 ,  A61K49/085 ,  A61K49/108

Abstract: An imaging nanoparticle comprising a plant virus particle having an interior surface and an exterior surface, an imaging agent that is linked to the interior and/or exterior surface, and a layer of biocompatible mineral such as silica coated over the exterior surface, is described. The imaging nanoparticle can be used in method of generating an image of a tissue region of a subject, by administering to the subject a diagnostically effective amount of an imaging nanoparticle and generating an image of the tissue region of the subject to which the imaging nanoparticle has been distributed.

公开(公告)号：US10072027B2

公开(公告)日：2018-09-11

申请号：US14112994

申请日：2012-04-17

Applicant: Johannes Platzek ,  Wilhelm Trentmann

Inventor： Johannes Platzek ,  Wilhelm Trentmann

IPC: C07F5/00 ,  A61K49/10 ,  C07D257/02

Abstract: What is described is a process for producing high-purity gadobutrol in a purity (according to HPLC) of more than 99.7 or 99.8 or 99.9% and the use for preparing a pharmaceutical formulation for parenteral administration. The process is carried out using specifically controlled crystallization conditions. The more recent developments in the field of the gadolinium-containing MR contrast agents (EP 0448191 B1, CA Patent 1341176, EP 0643705 B1, EP 0986548 B1, EP 0596586 B1) include the MRT contrast agent gadobutrol (Gadovist® 1.0) which has been approved for a relatively long time in Europe and more recently also in the USA under the name Gadavist®.

公开(公告)号：US20180214582A1

公开(公告)日：2018-08-02

申请号：US15748895

申请日：2016-08-01

Applicant: Albrecht Piiper

Inventor： Albrecht PIIPER ,  Christian SCHMITHALS ,  Thomas J. VOGL

IPC: A61K49/18 ,  A61K38/08 ,  G01R33/56 ,  A61K49/10 ,  A61B5/055 ,  A61K47/64

CPC classification number: A61K49/18 ,  A61B5/055 ,  A61K38/08 ,  A61K47/64 ,  A61K49/105 ,  G01R33/5601

Abstract: The present invention relates to an imaging diagnostic method, comprising a contrast agent including a contrast enhancer in a magnetic resonance imaging (MRI) assisted diagnosis of carcinoma diseases or carcinomas, in particular of hepatocellular carcinoma (HCC). The contrast agent is preferably a gadolinium compound, preferably Gd-DTPA including iRGD as a contrast enhancer, for the improved imaging of carcinomas, in particular HCC, in MRI. The invention furthermore relates to a method for the risk stratification of patients and subjects using the aforementioned diagnosis.

公开(公告)号：US09999690B2

公开(公告)日：2018-06-19

申请号：US14534474

申请日：2014-11-06

Applicant: Perosphere Inc.

Inventor： Bryan E. Laulicht ,  Sasha H. Bakhru ,  James Costin ,  Solomon S. Steiner

IPC: A61K49/10 ,  A61K51/04 ,  A61B6/00 ,  G01R33/56 ,  A61B5/00 ,  A61B5/055

CPC classification number: A61K49/10 ,  A61B5/055 ,  A61B5/4514 ,  A61B6/481 ,  A61B6/505 ,  A61B6/508 ,  A61K51/0459 ,  G01R33/5601

Abstract: Novel labeled compounds and metabolites thereof are disclosed, as well as pharmaceutical compositions including the compounds, and methods of using the labeled and unlabeled compounds, and specifically, 2-Amino-5-guanidino-pentanoic acid (3-{4-[3-(2-amino-5-guanidino-pentanoylamino)-propyl]-piperazin-1-yl}-propyl)-amide and metabolites thereof, for imaging, detecting and assessing disorders and diseases, such as arthritis and, more specifically, osteoarthritis by tracking proteoglycan and glycosaminoglycan content of cartilage. Also, pharmaceutical compositions comprising labeled and/or unlabeled 1,4-Bis(3-aminopropyl)piperazine are disclosed and methods of using the same.